Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2023-09-11 Regulatory Filings
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release issued by GeNeuro announcing the publication of a scientific study in the journal 'Translational Psychiatry'. It details the findings of the study regarding the link between SARS-CoV-2 and HERV-W activation in psychotic patients. Since this is a general regulatory announcement regarding company research and scientific developments that does not fit into specific financial reporting categories like 10-K, IR, or ER, it falls under the fallback category for regulatory announcements.
2023-09-11 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the publication of a scientific study in the journal 'Translational Psychiatry'. It details the findings of the study regarding the link between SARS-CoV-2, HERV-W retrovirus activation, and psychosis. While it mentions the company's ongoing clinical trials, it is primarily a corporate announcement regarding research developments and scientific publications, which falls under the category of general regulatory announcements or corporate news updates.
2023-09-11 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a short press release (under 5,000 characters) providing a summary of the company's cash position for the second quarter of 2023. It is an initial announcement of financial highlights rather than a full interim report, and it explicitly mentions the date for the upcoming 'First half financial results' report. Therefore, it fits the definition of an Earnings Release (ER). Q2 2023
2023-07-25 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro announcing its financial position (cash position) for the second quarter of 2023. It provides key highlights regarding cash flow and operational runway rather than a full comprehensive financial report. As it is a short announcement of quarterly financial highlights, it falls under the Earnings Release (ER) category. Q2 2023
2023-07-25 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 1% confidence The document is a 'Bilan semestriel du contrat de liquidité' (Half-year report on the liquidity contract) for GeNeuro. This type of document details the transactions made by a liquidity provider (Gilbert Dupont) on behalf of the company to maintain share liquidity. According to the provided definitions, reports regarding the company buying back or selling its own shares (or managing liquidity contracts for its own shares) fall under the 'Transaction in Own Shares' (POS) category.
2023-07-04 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Transaction in Own Shares Classification · 1% confidence The document is a 'Half-yearly report on the liquidity contract' for GeNeuro. It details the assets held in a liquidity account managed by Gilbert Dupont, including share counts and cash balances, along with a detailed appendix of daily transactions. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Paris to report on share buyback/liquidity programs. Since it is a periodic report on the company's own share transactions, it falls under the 'Transaction in Own Shares' category.
2023-07-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.